NanoViricides Inc. (NNVC)

[arvitar]

One can look at the poster and decide for themselves, (accessible through the company website).

One doesn't need to understand the technical details on the poster to understand its impact if true. Just consider NNVC's history of having 6000 previous animal studies with "spectacular results", and now adding one new cell culture study with positive results to that collection.

The results show that a few of NNVC's drug candidates appeared to be effective against VZV in their in vitro cell culture studies, and showed some specificity.

That would be "game changing" for NNVC investors if that was enough for Seymour to declare one of those candidates as being a lead worthy of further development. But apparently it is not. And if it is not enough to convince Seymour, then it is also not enough to convince anyone else.

If anything, it raises the question: If all these preclinical animal and cell culture studies have been showing great results for the past 12.5 years, why has the company still not identified a lead to take through IND approval and into clinical trials?

Especially in view of Seymour's claims of having done 6000 previous animal studies that all showed "spectacular results", and accumulating a $75,000,000.00 deficit in the process.

Preclincal studies in most therapeutic areas are notoriously poor predictors of how candidates will fare in IND tox studies and human clinical trials. One has to get there to find out, and still have enough backup cash to recover if a drug candidate fails along the way (failure is the statistical likelihood for any drug candidate regardless of how much preclincal data was accumulated).

Hence, the reason for those poor success-rates the FDA describes:

http://www.fdareview.org/03_drug_development.php